Waystar Considers Sale Amid Falling Market Value, Sources Reveal

Waystar, a healthcare software company specializing in payment management for hospitals and doctors, is reportedly considering a sale, according to sources familiar with the situation. The firm, which went public in New York two years ago, has engaged investment bank Evercore to explore its strategic options, including a potential sale that could see it return to private ownership.

Based in Lehi, Utah, and Louisville, Kentucky, Waystar has yet to make any definitive decisions, and plans could shift as the process unfolds, sources said. The company declined to comment on the matter, and Evercore has not responded to requests for comment.

Market Challenges and Strategic Positioning

Waystar's market value has diminished to approximately $4.8 billion, following a 24% decline in its share price this year. This downturn occurs amid a broader selloff affecting the software sector. Industry analysts have noted that investors initially supported Waystar's positioning as a technology company rather than a traditional healthcare services business. This strategy aimed to attract higher valuations typical for tech firms.

Despite initial enthusiasm that drove Waystar's share price from $20 to a peak of $45 in 2025, concerns over potential disruptions from artificial intelligence advancements have pressured the stock, according to a Morgan Stanley report from July.

Ownership and Investment Landscape

The company was formed in 2017 through the merger of Zirmed and Navicure, both involved in healthcare revenue management. Major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who took Waystar public in 2024. Currently, EQT holds the largest share with a 13% stake, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, as per data from LSEG.

Neither EQT nor CPPIB provided comments regarding the potential sale, and BlackRock also declined to comment. The exploration of a sale could test market interest in software companies amid fluctuating investor confidence.

Potential Outcomes and Industry Implications

Waystar's decision to consider a sale reflects broader challenges within the software sector, where companies face both market volatility and technological disruptions. The outcome of Waystar's exploration could provide insights into the current appetite for healthcare software firms and influence future strategic decisions in the industry.

As the situation develops, the healthcare software sector will be closely watching to see how Waystar navigates these challenges and whether it will ultimately proceed with a sale.